Wednesday, April 2, 2025

Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs

Related stories

Hacking the Hackers: How GenAI is Predicting and Preventing Cyber Attacks

In the high-stakes arena of cybersecurity, the rules of...

Veltris Acquires BPK to Boost AI & Digital in Healthcare

Veltris, a digital product engineering services provider backed by...

Accenture & Schaeffler Advance Industrial Humanoid Robots

Accenture has joined forces with Schaeffler AG to reshape...

EDGNEX Data Centers partners with Hyperco

The acquisition is expected to further strengthen the expansion...

Chef Robotics Raises $43M Series A to Scale AI Robotics

Chef Robotics, a leader in AI-powered robotic systems for...
spot_imgspot_img

Can-Fite signed an agreement with Collaborations Pharmaceuticals, a leading expert in Artificial Intelligence and Machine Learning

Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology and inflammatory diseases, today announced that it entered into an agreement with Collaborations Pharmaceuticals, Inc. (CPI) to develop anti-cancer drugs utilizing artificial intelligence (AI) and machine learning (ML) techniques. This project will aim to develop a next-generation A3 adenosine receptor drug agonists that significantly reduce the development time and cost of bringing such drugs to market.

CPI will utilize, apply and use AI and ML tools, including their MegaSyn generative AI method, to design new molecules with high affinity and selectivity to the A3AR Can-Fite target. CPI will also perform the chemical synthesis of the newly designed molecules with the ultimate goal of developing novel and robust anti-cancer drug candidates. Can-Fite will perform the testing of the biological anti-cancer effects and validate the molecular mechanism of the novel, chemically synthesized drug candidates.

Also Read: Dyno Therapeutics Launches Dyno eCap 1™ Vector, a Field-Leading AAV Capsid for Eye Gene Therapies

“Our vision is to deliver in silico small molecule drug candidates in a better and faster way to patients via a collaboration with Collaborations Pharmaceuticals. Our accumulated experience of bringing anti-cancer drugs which target the A3AR from lab to patients will be implemented into this AI drug development project,” stated Prof. Pnina Fishman, Executive Chairman and CSO at Can-Fite.

“We are delighted that Can-Fite chose our team of experts for this AI-led drug discovery collaboration and look forward to demonstrating what our technology can do,” said Sean Ekins, PhD, DSc., CEO and Founder of Collaborations Pharmaceuticals, Inc. We also look forward to complementing their outstanding scientific approach with our integrated technology platform and ability to generate novel and selective molecules.”

SOURCE: BusinessWire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img